Pathogenesis, diagnosis, and treatment of alcoholic liver disease

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Alcohol-related liver disease is a major cause of morbidity and mortality in the United States. Alcoholic liver disease encompasses a clinicohistological spectrum, including fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. Fatty liver is a benign and reversible condition, but progression to alcoholic hepatitis and cirrhosis is life-threatening. Alcoholic hepatitis is diagnosed predominantly on clinical history, physical examination, and laboratory testing, although liver biopsy is often necessary to secure the diagnosis. The major focus of management is abstinence from alcohol, supportive care, treatment of complications of infection and portal hypertension, and maintenance of positive nitrogen balance through nutritional support. Corticosteroid therapy is controversial but should be con sidered in patients with a discriminant function greater than 32 and/or presence of spontaneous hepatic encephalopathy in the absence of infection, gastrointestinal bleeding, and renal failure. The only curative therapy for advanced alcoholic cirrhosis is liver transplantation. Several recent advances in understanding the pathogenesis of alco- holic liver disease may lead to novel future treatment approaches, including inhibition of tumor necrosis factor α antioxidant therapy, stimulation of liver regeneration, and stimulation of collagen degradation.

Original languageEnglish (US)
Pages (from-to)1021-1029
Number of pages9
JournalMayo Clinic Proceedings
Volume76
Issue number10
StatePublished - 2001

Fingerprint

Alcoholic Liver Diseases
Alcoholic Hepatitis
Alcoholic Liver Cirrhosis
Fatty Liver
Alcohol Abstinence
Therapeutics
Liver Regeneration
Hepatic Encephalopathy
Nutritional Support
Portal Hypertension
Infection
Liver Transplantation
Physical Examination
Renal Insufficiency
Liver Diseases
Adrenal Cortex Hormones
Nitrogen
Collagen
Tumor Necrosis Factor-alpha
Antioxidants

Keywords

  • ALT = alanine aminotransferase
  • AST = aspartate aminotransferase
  • CAGE = alcoholism screening tool containing 4 structured questions
  • DF = discriminant function
  • GI = gastrointestinal
  • MCV = mean corpuscular volume
  • NF-κB = nuclear factor κB
  • TNF = tumor necrosis factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pathogenesis, diagnosis, and treatment of alcoholic liver disease. / Menon, K. V N; Gores, Gregory James; Shah, Vijay.

In: Mayo Clinic Proceedings, Vol. 76, No. 10, 2001, p. 1021-1029.

Research output: Contribution to journalArticle

@article{8d58a7c7529d48659aaf6fef6e21ca36,
title = "Pathogenesis, diagnosis, and treatment of alcoholic liver disease",
abstract = "Alcohol-related liver disease is a major cause of morbidity and mortality in the United States. Alcoholic liver disease encompasses a clinicohistological spectrum, including fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. Fatty liver is a benign and reversible condition, but progression to alcoholic hepatitis and cirrhosis is life-threatening. Alcoholic hepatitis is diagnosed predominantly on clinical history, physical examination, and laboratory testing, although liver biopsy is often necessary to secure the diagnosis. The major focus of management is abstinence from alcohol, supportive care, treatment of complications of infection and portal hypertension, and maintenance of positive nitrogen balance through nutritional support. Corticosteroid therapy is controversial but should be con sidered in patients with a discriminant function greater than 32 and/or presence of spontaneous hepatic encephalopathy in the absence of infection, gastrointestinal bleeding, and renal failure. The only curative therapy for advanced alcoholic cirrhosis is liver transplantation. Several recent advances in understanding the pathogenesis of alco- holic liver disease may lead to novel future treatment approaches, including inhibition of tumor necrosis factor α antioxidant therapy, stimulation of liver regeneration, and stimulation of collagen degradation.",
keywords = "ALT = alanine aminotransferase, AST = aspartate aminotransferase, CAGE = alcoholism screening tool containing 4 structured questions, DF = discriminant function, GI = gastrointestinal, MCV = mean corpuscular volume, NF-κB = nuclear factor κB, TNF = tumor necrosis factor",
author = "Menon, {K. V N} and Gores, {Gregory James} and Vijay Shah",
year = "2001",
language = "English (US)",
volume = "76",
pages = "1021--1029",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Pathogenesis, diagnosis, and treatment of alcoholic liver disease

AU - Menon, K. V N

AU - Gores, Gregory James

AU - Shah, Vijay

PY - 2001

Y1 - 2001

N2 - Alcohol-related liver disease is a major cause of morbidity and mortality in the United States. Alcoholic liver disease encompasses a clinicohistological spectrum, including fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. Fatty liver is a benign and reversible condition, but progression to alcoholic hepatitis and cirrhosis is life-threatening. Alcoholic hepatitis is diagnosed predominantly on clinical history, physical examination, and laboratory testing, although liver biopsy is often necessary to secure the diagnosis. The major focus of management is abstinence from alcohol, supportive care, treatment of complications of infection and portal hypertension, and maintenance of positive nitrogen balance through nutritional support. Corticosteroid therapy is controversial but should be con sidered in patients with a discriminant function greater than 32 and/or presence of spontaneous hepatic encephalopathy in the absence of infection, gastrointestinal bleeding, and renal failure. The only curative therapy for advanced alcoholic cirrhosis is liver transplantation. Several recent advances in understanding the pathogenesis of alco- holic liver disease may lead to novel future treatment approaches, including inhibition of tumor necrosis factor α antioxidant therapy, stimulation of liver regeneration, and stimulation of collagen degradation.

AB - Alcohol-related liver disease is a major cause of morbidity and mortality in the United States. Alcoholic liver disease encompasses a clinicohistological spectrum, including fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. Fatty liver is a benign and reversible condition, but progression to alcoholic hepatitis and cirrhosis is life-threatening. Alcoholic hepatitis is diagnosed predominantly on clinical history, physical examination, and laboratory testing, although liver biopsy is often necessary to secure the diagnosis. The major focus of management is abstinence from alcohol, supportive care, treatment of complications of infection and portal hypertension, and maintenance of positive nitrogen balance through nutritional support. Corticosteroid therapy is controversial but should be con sidered in patients with a discriminant function greater than 32 and/or presence of spontaneous hepatic encephalopathy in the absence of infection, gastrointestinal bleeding, and renal failure. The only curative therapy for advanced alcoholic cirrhosis is liver transplantation. Several recent advances in understanding the pathogenesis of alco- holic liver disease may lead to novel future treatment approaches, including inhibition of tumor necrosis factor α antioxidant therapy, stimulation of liver regeneration, and stimulation of collagen degradation.

KW - ALT = alanine aminotransferase

KW - AST = aspartate aminotransferase

KW - CAGE = alcoholism screening tool containing 4 structured questions

KW - DF = discriminant function

KW - GI = gastrointestinal

KW - MCV = mean corpuscular volume

KW - NF-κB = nuclear factor κB

KW - TNF = tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0034784358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034784358&partnerID=8YFLogxK

M3 - Article

C2 - 11605686

AN - SCOPUS:0034784358

VL - 76

SP - 1021

EP - 1029

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -